News

Graftys renforce son organisation

Créée en 2005, la société Graftys développe, fabrique et commercialise des ciments osseux synthétiques résorbables pour la chirurgie réparatrice osseuse. Commercialisées en Europe, aux USA et dans de nombreux autres pays, les technologies mises au point par Graftys avec ses partenaires offrent des solutions thérapeutiques innovantes pour de nombreuses applications en ortho-traumatologie.

Graftys recherche:
- un/une Commercial & Business Development Manager (job description ici)
- un/une Chief Business Officer (job description ici)
- un/une Regulatory Affairs Manager (job description ici)
- un/une Assistant to CEO (job description ici)


Read more

Minoryx Therapeutics receives approval to initiate phase 2 study in Friedreich’s Ataxia

The phase 2 trial, FRAMES, is expected to start patient enrollment in the coming weeks in the Hospital La Paz (Madrid), lead by Dr. Francisco Javier Rodríguez de Rivera. The company is also working to open additional sites at medical institutions in Belgium, Germany and France. The upcoming trial is designed to be double-blind and placebo-controlled with the aim of assessing the efficacy and safety of MIN-102 in Friedreich’s Ataxia patients.  For more information please find the press release here.  

Read more